Overview

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Molsidomine used as an add-on treatment on standard care therapy should be superior to placebo used also as an add-on treatment on standard care therapy on improving the endothelial function (endothelium score measured by reactive hyperemia - peripheral arterial tonometry [RH-PAT]) after 12 months of treatment in patients with stable angina patients and undergoing elective percutaneous coronary intervention. The study will be double-blind, parallel-group, randomised, multicentre, sequential, placebo-controlled study. The device used to determine RH-PAT will be EndoPAT. Duration of the treatment = one year.
Phase:
Phase 4
Details
Lead Sponsor:
Therabel Pharma SA/NV
Treatments:
Molsidomine